In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With DxS, Qiagen Moves into Personalized Medicine

Executive Summary

Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.

You may also be interested in...



Companion Diagnostics Move Toward Mainstream Drug Development

With FDA planning to release guidelines on companion diagnostics by year's end, private sector activity around biomarkers appears ready to accelerate. Pharma companies are taking different strategies to incorporate companion diagnostics into their drug development programs, and experimenting with different applications for co-developed products. The relationship between Pharma and diagnostics companies is evolving, with Pharma leading the way. The pace of dealmaking is picking up, but in negotiating partnerships, both sides are still struggling with how to reconcile their different business models, cost structures, and appetites for risk.

Companion Diagnostics Move Toward Mainstream Drug Development

With FDA planning to release guidelines on companion diagnostics by year's end, private sector activity around biomarkers appears ready to accelerate. Pharma companies are taking different strategies to incorporate companion diagnostics into their drug development programs, and experimenting with different applications for co-developed products. The relationship between Pharma and diagnostics companies is evolving, with Pharma leading the way. The pace of dealmaking is picking up, but in negotiating partnerships, both sides are still struggling with how to reconcile their different business models, cost structures, and appetites for risk.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009

Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel